First Read: Rohto Pharmaceutical "FY3/26: Asia strength offsets margin drag"

Research evidence excerpt

First Read: Rohto Pharmaceutical "FY3/26: Asia strength offsets margin drag"

Forecast returns

Forecast price appreciation 11.7%

Forecast dividend yield 1.7%

Forecast stock return 13.4%

Market return assumption 7.6%

Forecast excess return 5.8%

Company Description

Rohto Pharmaceutical, founded in 1899, manufactures digestive medicines, eye drops, and

skin-care products and holds the top share in Japan's mass-market eye-drop segment. Brands

include Mentholatum, Obagi, and Pansiron. Revenue is mainly OTC consumer; Japan is core,

with Asia rising. Rohto eye care and Mentholatum are well known in China. Recent activity

includes the R:STEM cell-culture medium, certified under Japan's FIRM Mark.

Valuation Method and Risk Statement

We value Rohto using a forward price to earnings multiple applied to consumer health

earnings.

Upside risks include: Rohto’s upside potential lies in strong execution across its consumer

healthcare R&D pipeline for innovative products. Successful launches in these segments could

drive revenue growth beyond current forecasts. Expansion into emerging markets and new

therapeutic areas would add incremental upside, particularly if supported by stable pricing

and favorable reimbursement policies. Innovation in consumer health, including OTC and

cosmetic products, could further diversify earnings streams. Operational efficiency initiatives,

such as supply chain optimization and cost control, may also contribute to margin expansion,

amplifying overall performance.

Donwnside risks include: (1) sales and margin contraction due to market slowdown and

intensified competition; (2) underperformance of Japan and Asia growth or gross margin mix;

(3) competition in CDMO and tool initiatives; (4) potential manufacturing issues; (5) adoption